Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced on Wednesday that it is presenting the first clinical data for a cancer treatment aimed at the Hippo pathway at the American Association for Cancer Research (AACR) Annual Meeting 2023.
The outcome from the firm's Phase one clinical study of its first-in-class transcriptional improved associate domain (TEAD) autopalmitoylation inhibitor, VT3989, will be revealed by Timothy A. Yap, PhD., of the University of Texas, M.D. Anderson Cancer Center, during an oral plenary session at the conference.
The Phase one study, a multi-centre, open label trial, tested the product in subjects with refractory metastatic solid tumours, including refractory pleural malignant mesothelioma. It included a dose escalation and a dose expansion phase. The latter of which also enrolled subjects with neurofibromatosis 2 (NF2) mutant tumours.
The product inhibits palmitoylation of members of the TEAD protein family, including both covalent and non-covalent inhibitors. Pre-clinical research and development activities have indicated that the product is active as a monotherapy against tumours that rely upon dysfunction of the Hippo pathway, and in combination with other anti-cancer therapies in additional tumour types.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration